Across tumor types, KRAS-mutated tumors had a higher TMB versus KRAS wild-type tumors (Supplementary Fig. 7b; P = 3 × 10−22, Wilcoxon rank-sum; P = 0.013 after controlling for MSI status using MANTIS) but was also lost after controlling for tumor type (P = 0.58, multivariate linear regression). The gene discussed is KRAS; the disease is neoplasm.